Eton Pharmaceuticals Share Price (NASDAQ: ETON)

$17.3

▲

0.02

(0.12%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Eton Pharmaceuticals Stock chart to analyse performance

Eton Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$17.11
Today's High:$17.40
$17.30
1.1%
Downside
Day's Volatility :1.67%
Upside
0.57%
52 Weeks Low:$4.47
52 Weeks High:$21.48
$17.30
74.16%
Downside
52 Weeks Volatility :79.19%
Upside
19.46%

Eton Pharmaceuticals Stock Returns

Period	Eton Pharmaceuticals Inc	Index (Russel 2000)
3 Months	-8.12%	0.0%
6 Months	15.17%	0.0%
1 Year	276.3%	0.0%
3 Years	398.85%	-4.7%

Eton Pharmaceuticals Inc Key Stats

Check Eton Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.28
Open	$17.19
Today's High	$17.4
Today's Low	$17.11
Market Capitalization	$464.2M
Today's Volume	$160.3K
52 Week High	$21.48
52 Week Low	$4.47
Revenue TTM	$58.2M
EBITDA	$4.5M
Earnings Per Share (EPS)	$-0.15
Profit Margin	-7.1%
Quarterly Earnings Growth YOY	-0.13%
Return On Equity TTM	-22.06%

Stock Returns calculator for Eton Pharmaceuticals Stock including INR - Dollar returns

The Eton Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Eton Pharmaceuticals investment value today

Current value as on today

₹3,81,371

Returns

₹2,81,371

(+281.37%)

Returns from Eton Pharmaceuticals Stock

₹2,76,087 (+276.09%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Eton Pharmaceuticals Stock

-18%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Eton Pharmaceuticals Stock from India on INDmoney has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Eton Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
Opaleye Management Inc
10.66%
EcoR1 Capital, LLC
7.57%
Vanguard Group Inc
4.89%
Nantahala Capital Management, LLC
4.39%
Westside Investment Management, Inc.
1.76%
Susquehanna International Group, LLP
1.67%

Analyst Recommendation on Eton Pharmaceuticals Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Eton Pharmaceuticals(by analysts ranked 0 to 5 stars)

Eton Pharmaceuticals Share Price Target

What analysts predicted

Upside of 73.41%

Target:

$30.00

Current:

$17.30

Eton Pharmaceuticals share price target is $30.00, a slight Upside of 73.41% compared to current price of $17.30 as per analysts' prediction.

Eton Pharmaceuticals Stock Insights

Price Movement
In the last 1 year, ETON stock has moved up by 276.3%
Increasing Revenue
Revenue is up for the last 8 quarters, 7.02M → 18.92M (in $), with an average increase of 12.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, 627.0K → -2.58M (in $), with an average decrease of 140.9% per quarter

Eton Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$959.0K	-
Net Income	$-18.3M	↑ 43.8%
Net Profit Margin	-1.9K%	-

	FY20	Y/Y Change
Revenue	$39.0K	↓ 95.93%
Net Income	$-28.0M	↑ 52.67%
Net Profit Margin	-71.7K%	↓ 69807.63%

	FY21	Y/Y Change
Revenue	$21.8M	↑ 55879.49%
Net Income	$-2.0M	↓ 93.01%
Net Profit Margin	-8.95%	↑ 71709.0%

	FY22	Y/Y Change
Revenue	$21.3M	↓ 2.66%
Net Income	$-9.0M	↑ 361.43%
Net Profit Margin	-42.45%	↓ 33.5%

	FY23	Y/Y Change
Revenue	$31.6M	↑ 48.9%
Net Income	$-936.0K	↓ 89.62%
Net Profit Margin	-2.96%	↑ 39.49%

	FY24	Y/Y Change
Revenue	$39.0M	↑ 23.29%
Net Income	$-3.8M	↑ 308.44%
Net Profit Margin	-9.8%	↓ 6.84%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$8.0M	↑ 8.93%
Net Income	$-811.0K	↓ 64.05%
Net Profit Margin	-10.18%	↑ 20.67%

	Q2 FY24	Q/Q Change
Revenue	$9.1M	↑ 13.91%
Net Income	$-3.0M	↑ 274.97%
Net Profit Margin	-33.51%	↓ 23.33%

	Q3 FY24	Q/Q Change
Revenue	$10.3M	↑ 13.78%
Net Income	$627.0K	↓ 120.62%
Net Profit Margin	6.07%	↑ 39.58%

	Q4 FY24	Q/Q Change
Revenue	$11.6M	↑ 12.81%
Net Income	$-598.0K	↓ 195.37%
Net Profit Margin	-5.13%	↓ 11.2%

	Q1 FY25	Q/Q Change
Revenue	$17.3M	↑ 48.38%
Net Income	$-1.6M	↑ 162.88%
Net Profit Margin	-9.1%	↓ 3.97%

	Q2 FY25	Q/Q Change
Revenue	$18.9M	↑ 9.52%
Net Income	$-2.6M	↑ 64.44%
Net Profit Margin	-13.66%	↓ 4.56%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$506.0K	↓ 903.17%

	FY20	Y/Y Change
Profit	$-247.0K	↓ 148.81%

	FY21	Y/Y Change
Profit	$19.2M	↓ 7876.92%

	FY22	Y/Y Change
Profit	$14.3M	↓ 25.46%

	FY23	Y/Y Change
Profit	$21.1M	↑ 47.09%

	FY24	Y/Y Change
Profit	$23.4M	↑ 11.16%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$5.0M	↑ 37.93%

	Q2 FY24	Q/Q Change
Profit	$5.6M	↑ 12.36%

	Q3 FY24	Q/Q Change
Profit	$6.3M	↑ 12.02%

	Q4 FY24	Q/Q Change
Profit	$6.5M	↑ 2.76%

	Q1 FY25	Q/Q Change
Profit	$9.9M	↑ 52.27%

	Q2 FY25	Q/Q Change
Profit	$11.9M	↑ 20.92%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-18.0M	↑ 121.31%
Investing Cash Flow	$-1.8M	↑ 682.2%
Financing Cash Flow	$5.2M	↓ 76.31%

	FY20	Y/Y Change
Operating Cash Flow	$-22.3M	↑ 23.97%
Investing Cash Flow	$-50.0K	↓ 97.29%
Financing Cash Flow	$31.6M	↑ 507.82%

	FY21	Y/Y Change
Operating Cash Flow	$-4.7M	↓ 78.87%
Investing Cash Flow	$-2.6M	↑ 5018.0%
Financing Cash Flow	$391.0K	↓ 98.76%

	FY22	Y/Y Change
Operating Cash Flow	$4.8M	↓ 202.12%
Investing Cash Flow	$-2.8M	↑ 8.95%
Financing Cash Flow	$-134.0K	↓ 134.27%

	FY23	Y/Y Change
Operating Cash Flow	$6.8M	↑ 41.36%
Investing Cash Flow	$-775.0K	↓ 72.2%
Financing Cash Flow	$-957.0K	↑ 614.18%

	FY24	Y/Y Change
Operating Cash Flow	$969.0K	↓ 85.78%
Investing Cash Flow	$-40.0M	↑ 5063.1%
Financing Cash Flow	$32.6M	↓ 3505.75%

Q1 FY24

Q3 FY24

Q4 FY24

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.5M	↓ 739.02%
Investing Cash Flow	$-1.9M	↑ 142.84%
Financing Cash Flow	$-378.0K	↑ 28.57%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.0M	↑ 135.22%
Investing Cash Flow	$1.9M	-
Financing Cash Flow	$-385.0K	↑ 78.24%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-765.0K	↓ 125.91%
Investing Cash Flow	$-38.1M	↓ 2141.33%
Financing Cash Flow	$33.6M	↓ 8820.0%

Eton Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Eton Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Eton Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Eton Pharmaceuticals Inc	22.25%	15.17%	276.3%	398.85%	398.85%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Eton Pharmaceuticals Inc	120.67	NA	NA	0.48	-0.22	0.02	NA	0.89
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Eton Pharmaceuticals Inc	Buy	$464.2M	398.85%	120.67	-7.1%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Organization	Eton Pharmaceuticals
Employees	31
CEO	Mr. Sean E. Brynjelsen
Industry	Health Technology

Key Management of Eton Pharmaceuticals Inc

Name	Title
Mr. Sean E. Brynjelsen	President, CEO & Director
Mr. David C. Krempa	Chief Business Officer
Ms. Ipek Erdogan-Trinkaus	Chief Commercial Officer
Danka Radosavljevic	Executive Vice President of Operations
Mr. Scott Grossenbach	Senior Vice President of Sales Operations

Important FAQs about investing in ETON Stock from India :

What is Eton Pharmaceuticals share price today?

Eton Pharmaceuticals share price today is $17.30 as on August 30, 2025 at 1:29 am IST at the close of the market. Eton Pharmaceuticals share today touched a day high of $17.40 and a low of $17.11.

What is the 52 week high and 52 week low for Eton Pharmaceuticals share?

Eton Pharmaceuticals share touched a 52 week high of $21.48 and a 52 week low of $4.47. Eton Pharmaceuticals stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $17.30, lower by 19.46% versus the 52 week high.

How to invest in Eton Pharmaceuticals Stock (ETON) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Eton Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eton Pharmaceuticals Shares that will get you 0.0867 shares as per Eton Pharmaceuticals share price of $17.30 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Eton Pharmaceuticals Stock (ETON) from India?

Indian investors can start investing in Eton Pharmaceuticals (ETON) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Eton Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Eton Pharmaceuticals share’s latest price of $17.30 as on August 30, 2025 at 1:29 am IST, you will get 0.5780 shares of Eton Pharmaceuticals. Learn more about fractional shares .

What are the returns that Eton Pharmaceuticals has given to Indian investors in the last 5 years?

Eton Pharmaceuticals stock has given 398.85% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?